DERM News

It was another busy week for the IPO market as 15 new issuers went public, with Rivian (RIVN) in the spotlight. The pre-revenue electric truck developer became the largest IPO of 2021, raising nearly $12 billion in the largest IPO since Alibaba (NYSE: BABA) in 2014, and popped 29% in its public debut. Rivian Automotive (RIVN) upsized and priced...read more

Journey Medical, which owns a portfolio of acquired drugs marketed for skin conditions, announced terms for its IPO on Monday. The Scottsdale, AZ-based company plans to raise $35 million by offering 3.2 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Journey Medical would command a fully diluted market value of $203 million. Journey Medical is...read more

Journey Medical, a commercial-stage pharma with a portfolio of dermatological drugs, filed on Friday with the SEC to raise up to $40 million in an initial public offering. Journey Medical is focused on the development and commercialization of pharmaceuticals for the treatment of dermatological conditions. Its current portfolio includes five branded (Qbrexza, Accutane, Targadox,...read more

DermTech, which is developing non-invasive gene expression tests to diagnosis various skin conditions, withdrew its plans for an initial public offering on Thursday citing poor market conditions. Skin-related biotech IPO Dermira (DERM) raised $125 million in October by pricing at the high end of the range, and now trades about 1.5% above the offer price. The La Jolla, CA...read more